Cellectar Bioscience Inc., a Florham Park-based biopharmaceutical company focused on treating cancer, announced on Tuesday it has appointed Dr. Igor Grachev as chief medical officer.
“I am excited to welcome Igor to our senior management team as Chief Medical Officer. Igor possesses outstanding academic training and a track record of professional success with highly relevant experiences including multiple global oncology drug approvals,” Cellectar CEO Jim Caruso said. “We look forward to his leadership as we advance our pipeline of assets and work towards fully developing the potential of CLR 131.”
Grachev has nearly 20 years of industry experience, most recently serving as global development leader and head of innovation trials initiative, R&D for TEVA Branded Specialty Pharmaceuticals. He’s also held clinical development and medical affairs leadership roles at GE Healthcare, Novartis, GSK, Merck, Schering Plough, Sanofi-Aventis, and BioClinica.
He also was the former assistant professor of radiology at SUNY Upstate Medical Univesrity and as a fellow in radiology at Massachusetts General Hospital, Harvard Medical School.
“I am excited to join Cellectar and help deliver on the promise of CLR 131. I believe Cellectar’s novel delivery vehicle provides a unique opportunity to create a truly targeted radiotherapeutic with the potential to be a meaningful therapy in a variety of oncology indications. I look forward to bringing CLR 131 to market and making a difference in patients’ lives,” Grachev said.
